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Background The cost-utilityof brief
therapycomparedwith cognitive^
behavioural therapy (CBT) and care as
usual in the treatmentof depression and
anxietyhas not yet been determined.
Aims To assess the cost-utilityof brief
therapycomparedwith CBTand care as
usual.
Method Apragmatic randomised
controlled trial involving 702 patients
was conducted at 7 Dutchmental
healthcare centres (MHCs).Patients
were interviewed at baseline and then
every 3 months over a period of1.5 years,
duringwhichtime datawere collected on
directcosts, indirectcosts and qualityof
life.
Results Themean directcosts of
treatment atthe MHCswere significantly
lower for brief therapy than for CBTand
care as usual.However, after factoring in
otherhealthcare costs and indirectcosts,
no significantdifferencesbetweenthe
treatmentgroups could be detected.We
foundno significantdifferences in quality-
adjusted life-years betweenthe groups.
Conclusions Cost-utilitydidnotdiffer
significantly betweenthe three treatment
groups.
Declaration of interest None.
Fundingdetailed in Acknowledgements.
Time-limited psychotherapy has been intro-
duced partly in response to economic con-
siderations and partly because of patient
preferences for brief interventions (Jarrett
& Rush, 1994). In addition, the demand
for psychological treatment appears to have
been motivated by concerns about the side-
effects of medication and about potential
drug dependency, and by a reluctance to
use biochemical therapy to resolve psycho-
logical problems (Churchill et al, 2001).
In The Netherlands, psychological treat-
ment is generally provided by out-patient
mental healthcare centres (MHCs, the
former Regional Institutes for Ambulatory
Mental Health).
At these MHCs, an approach known as
brief therapy, namely a short-term psycho-
logical treatment consisting of a maximum
of seven sessions, is currently growing in
popularity. The aim of this study was to
assess the long-term cost-effectiveness of
brief therapy compared with cognitive–
behavioural therapy (CBT) and care as
usual as a first-line treatment in an MHC
out-patient population. We used a




The study was a large multicentre random-
ised trial conducted in MHCs in The
Netherlands. The MHCs are specialised
mental healthcare institutes to which
patients must be referred by a general
practitioner (GP). Seven MHCs (Altrecht,
Eleos, Emergis, Gelderse Roos, Mentrum,
Zaanstreek/Waterland and Adhesie) parti-
cipated in the study and were representative
of the patient population. Patient selection
was undertaken in two steps. Enrolment
took place between February 2000 and
October 2001, and follow-up data were
collected until March 2003. First, during
this period a total of 6095 new clients
presented to the MHCs and were screened
with regard to inclusion criteria (age 18–
65 years, eligible for out-patient mental
healthcare, not treated by the same MHC
in the past year) and exclusion criteria (psy-
chotic or bipolar disorder, cognitive impair-
ment, high suicide risk, poor command of
the Dutch language, hard drug misuse/
dependence). Comorbidity associated with
other psychiatric diagnoses (with the excep-
tion of psychotic or bipolar disorder) was
allowed, and this included personality
disorders, alcohol misuse/dependence and
somatic disorders. Second, all of the
remaining patients were assessed with the
Composite International Diagnostic Inter-
view (CIDI; Wittchen, 1994). Patients with
the following DSM–IV diagnoses (Ameri-
can Psychiatric Association, 1994) were in-
cluded: major depressive disorder (single
episode or recurrent); dysthymic disorder;
panic disorder (with or without agorapho-
bia); social phobia; or generalised anxiety
disorder. Over a fifth of the interviewed pa-
tients were excluded (n¼1338; 22%) or else
failed to meet the inclusion criteria
(n¼1257; 21%). Nearly a third of the pa-
tients (n¼1995; 33%) refused to partici-
pate, and 803 (13%) were not included
for other reasons (e.g. not contactable be-
cause telephone number was incorrect, on
holiday). In total, 702 patients gave their
informed consent and were included in the
study. This sample was somewhat smaller
than the pre-set sample size of 750 patients.
A follow-up period of 1.5 years was
chosen to establish the long-term effects
on health status and costs. Measurements
were recorded at baseline and then every
3 months. Patients were permitted to
switch to an alternative treatment arm if
their medical condition rendered this
necessary. We applied intention-to-treat
analyses.
Interventions
Brief therapy is a formalised ‘stepped-care’
approach. The therapy focuses mainly on
the present, and emphasises abilities rather
than disabilities. Brief therapy is expected
to reduce costs and increase efficiency in
the short term. Its claim to long-term cost-
effectiveness in the Dutch mental health-
care setting for a broad range of psychiatric
problems has not yet been confirmed by
scientific evidence. Problems may recur at
a later date, or patients may require
additional treatment in mental healthcare
services or other parts of the healthcare
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sector and consequently generate additional
costs. In the present study, patients who
were undergoing brief therapy for depres-
sion or anxiety were compared with those
who were receiving CBT, which had been
shown by earlier studies to be an effective
approach (Black et al, 1993; Cloaguan et
al, 1998; Dorrepaal et al, 1998). In this
study, CBT was formalised and the main
focus was on altering irrational cognitions
by challenging them. The maximum num-
ber of sessions was 15. In the same way
as for brief therapy, a ‘stepped-care’ ap-
proach was adopted for CBT, in which all
patients initially received a first-line treat-
ment, and they were only switched to an-
other therapy if the first therapy proved to
be inadequate. In The Netherlands, care
as usual is not formalised, and a multidisci-
plinary team is free to assign a therapy from
a wide range of therapeutic options. The
treatment decision is based on professional
experience, taking into account the specific
problems and characteristics of the individ-
ual patient. The number of sessions de-
pends on the therapy that is offered.
Evidence on the (cost-)effectiveness of care
as usual is lacking. However, this type of
‘matched care’ is claimed to be more effec-
tive than a ‘stepped-care’ approach, in
which one form of (relatively brief) therapy
is started for all patients indiscriminately,
and patients are switched to other options
if there is no subsequent improvement or
if side-effects occur.
Measures
At baseline, several demographic character-
istics (e.g. age, gender, educational level
and employment status) were assessed. In
all interviews that were conducted during
treatment, we assessed health-related
quality of life, use of medical resources
and productivity loss using the EuroQol
Questionnaire (EQ–5D) (Essink-Bot et al,
1993) and the Trimbos and iMTA Ques-
tionnaire on Costs Associated with Psychi-
atric Illness (TiC–P; Hakkaart-van Roijen,
2002).
Quality of life
Quality of life was assessed with the EQ–
5D, which is a validated tool for measuring
general health-related quality of life. It con-
sists of five items (mobility, self-care, usual
activities, pain/discomfort and anxiety/
depression), each of which is rated as
causing ‘no problems’, ‘some problems’ or
‘extreme problems’. The health descriptions
can be linked directly to empirical values
for health states of the general public,
which allows utilities to be computed
(Essink-Bot et al, 1993). The patient mean
utility scores were estimated by applying
the area-under-the-curve method, which
involves summing the areas of the geo-
metrical shapes obtained by linearly inter-
polating between utility scores over the
study period (Matthews et al, 1990).
Direct and indirect costs
The economic evaluation was undertaken
from a societal perspective, and included
costs due to medical resource utilisation
(direct medical costs) and costs attributable
to production losses (indirect costs).
We used the TiC–P to collect data on
direct and indirect costs from the patients
(Hakkaart-van Roijen, 2002). The first part
of the Tic–P measures medical resource
utilisation by asking for the number of
contacts with different (medical and
psychological) healthcare providers (e.g.
GP, psychiatrist, medical specialist, phys-
iotherapist, alternative health practitioner,
day care/hospital length of stay, and medi-
cation) during the past 4 weeks. We as-
sumed that the number of contacts and/or
days in those 4 weeks were representative
of the total period between assessment
points (an average of 3 months). Data on
the number of contacts at the MHCs were
collected directly from the participating
centres. Subsequently, the number of medi-
cal contacts was multiplied by the unit costs
for 2002 (Oostenbrink et al, 2000; College
for Health Insurance (CVZ), 2002). All
costs were estimated for the year 2002
and are presented in euros.
The second part of the TiC–P measures
productivity losses and includes a short ver-
sion of the Health and Labour Question-
naire (van Roijen et al, 1996; Dam et al,
1998). Data on the number of days of ab-
sence from work were divided into short-
term and long-term absence from work.
Short-term absence referred to periods of
less than 2 weeks. When calculating the in-
direct costs due to short-term absence from
work, we assumed that the number of days
lost over the past 2 weeks was representa-
tive of the total period between the mea-
surement points (an average of 3 months).
However, if respondents indicated that they
had been absent for the whole of the past 2
weeks, we collected additional information
concerning when this period of long-term
absenteeism had begun, as the recall period
for long-term absence from work was de-
termined by the start of this period. This
additional information was used to value
the production losses according to the fric-
tion cost method (Koopmanschap et al,
1995; Koopmanschap & Rutten, 1996).
The period of time needed to replace a
worker (the so-called ‘friction period’) in
2002 is estimated to be 154 days. Absentee-
ism among workers was valued by the aver-
age production value by age and gender per
day or per hour.
Patients may go to work despite being ill,
which may impair job performance. There-
fore all patients who had worked were asked
if they had experienced ‘no impediment’ or
‘some/considerable impediments’.
Data analysis
Costs and quality-adjusted life-years
The results of the cost and quality-adjusted
life-year (QALY) analyses are presented as
mean values with standard errors. Data
on the number of contacts at the MHC
were collected directly at the centres, and
therefore data were available for nearly all
patients (n¼611; 87%). However, data on
healthcare utilisation and absence from
work for estimating other health costs and
indirect costs and quality of life were col-
lected by means of a questionnaire. At base-
line, data from the TiC–P and the EQ–5D
were available for 646 (92%) of the partici-
pants in all treatment groups. At the 1-year
follow-up and 1.5-year follow-up, data
from the TiC–P and the EQ–5D were avail-
able for 423 (60%) and 394 (56%) of the
respondents respectively. Data with regard
to individual resource-use items were
unavailable for a small proportion (3%)
of patients.
To account for the missing data and the
additional uncertainty that they introduce,
we used the multiple imputation technique
in which each missing value is replaced by
m41 simulated values (Rubin, 1987;
Rubin & Schenker, 1991; Lavori et al,
1995). After the multiple imputations have
been created, m plausible versions of the
complete data exist, each of which is ana-
lysed by standard methods. The results of
the multiple imputation analyses are then
combined to produce a single result that in-
cludes uncertainty owing to the missing
data (Rubin & Schenker, 1991; Rubin,
1996; Schafer, 1997). For the proportion
of missing data in the present study,
m¼10 was found to be sufficiently large
to stabilise the outcomes in terms of the
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standard errors for all analyses (Schafer,
1997). The overall mean costs are simply
calculated as the mean of the mean costs
in each data-set. The overall associated var-
iance is determined by combining the var-
iance within data-sets with the variance
between data-sets (Schafer, 1997). We used
the Monte Carlo Markov Chain approach
to impute the missing values. This approach
assumes that the underlying distribution is
multivariate normal. However, it has been
shown in a large simulation study that even
with skewed data this method often per-
forms well (Oostenbrink & Al, 2005).
Standard errors were derived both by
the parametric approach as suggested by
Rubin (1996) and by a (non-parametric)
bootstrap procedure (Rubin & Schenker,
1991). However, because these two methods
yielded equivalent results, only the para-
metric standard errors are presented here.
Cost-utility
Cost-utility was evaluated by relating the
difference in direct medical costs per
patient who received either brief therapy
or the control treatment (CBT or care as
usual) to the difference in terms of QALYs
gained, which yielded an estimate of cost
per QALY. In addition, we estimated the
cost per QALY including the indirect costs.
Uncertainty was assessed by means of
bootstrapping, and the results are presented
as acceptability curves (van Hout et al,
1994). Since we were dealing here with
three interventions instead of two, we used
an adjusted version of the acceptability
curve, which leads to a cost-effectiveness
frontier that indicates which treatment is
optimal for various threshold incremental
cost-effectiveness ratios (Fenwick et al,
2001).
Sensitivity analyses
The way in which missing data are handled
is vitally important when assessing the
results of economic evaluations (Oosten-
brink et al, 2003; Oostenbrink & Al,
2005). Therefore two alternative methods
for imputing missing data, namely linear
extrapolation and complete case analysis,
were applied in the sensitivity analysis.
Applying linear extrapolation, the other
healthcare costs and costs due to short-term
absence from work were extrapolated to
1.5 years by dividing the observed costs of
each patient by the number of observed
days for which the patient remained in the
study, and multiplying the results by 548.
The complete case analysis excluded the
data for all patients who dropped out of the
study before the 1.5-year follow-up.
Statistical analysis
Multiple imputation analysis was performed
using PROC ‘MI’ in SAS for Windows
(available in version 8.02 and higher). All
other statistical analyses were performed
using SPSS version 10.1 for Windows.
RESULTS
The initial characteristics of the patients in
the three treatment arms were fairly similar
with regard to key variables (Table 1). In
total, 41% of the patients had both a mood
disorder and an anxiety disorder, 47% had
a mood disorder only and 12% had an
anxiety disorder only. Over half of the
patients who were in paid employment
had been absent for a period of over 2
weeks at baseline. More than 40% of the
patients who were not in paid employment
indicated that this was a result of health
problems. At baseline, the mental health
functioning of the patients in the CBT
group was significantly lower than that of
patients in the brief therapy group (Table 1).
At baseline, there were no statistically
significant differences in demographic data,
health status or costs between the group for
which there was a complete data set and
the respondents who were lost to follow-
up.
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Age (years): mean (s.d.) 36 (10) 36 (10) 37 (10) 36 (10)
Gender (% male) 35 40 43 39
DSM^IVdiagnosis1 (%)
First depression, mild 12 12 10 11
First depression, moderate 16 14 13 15
First depression, severe 23 28 20 24
Recurrent depression, mild 14 14 20 16
Recurrent depression, moderate 10 10 10 10
Recurrent depression, severe 11 8 12 11
Dysthymia 24 28 28 27
Panic disorder without agoraphobia 13 12 15 13
Panic disorder with agoraphobia 23 21 23 22
Social phobia 26 29 26 27
Generalised anxiety 3 6 3 4
Respondents in paid employment (%) 62 68 70 66
Paid employment (hours/week): mean (s.d.) 29 (11.3) 31 (10.4) 32 (10.7) 31 (10.9)
Respondents in paid employment2
No impediments at work (%) 13 12 16 14
Impediments at work (%) 30 30 33 31
Absent for42 weeks (%) 16 11 12 13
Absent for42 weeks (%) 57 57 50 55
Respondents not in paid employment
Care for household (%) 38 43 34 38
Health problems (%) 48 43 39 44
Receiving pension (%) 3 1 1 2
Student (%) 4 8 6 6
Other3 (%) 8 5 20 11
EQ^5D utility score 0.51 0.52 0.53 0.52
CBT, cognitive^behavioural therapy; EQ^5D, EuroQol Questionnaire.
1. Patientmay havemore than one diagnosis.
2. Patientmay have reported impediments at work and short-term absence fromwork.
3. For example, unemployed, voluntary worker.
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Direct and indirect costs
Table 2 shows the estimated total mean
direct medical costs and indirect costs per pa-
tient over a period of 1.5 years. As was ex-
pected, the mean number of contacts and
the associated costs in the MHCs were sig-
nificantly lower in the brief therapy group
than in the CBT group (95% CI e169 –
e741) or the usual care group (95% CI
e14 – e464). However, no significant differ-
ence was found between the three treatment
groups with regard to the mean total direct
medical costs per patient (i.e. including the
costs due to resource utilisation in other
parts of the healthcare service), nor was there
a significant difference in indirect costs
between the three treatment groups.
Over time, for all treatment groups the
percentage of patients in paid employment
who had long-term absence from work
declined, and conversely the percentage of
patients who had no impediments increased
(Table 3).
Quality of life
The utility scores for the three treatment
groups also showed significant improve-
ment during the study period and did not
differ significantly between the groups
(Table 4). The improvement in utility
scores was moderate during the first year,
but was low during the final 6 months of
follow-up (Cohen, 1988). At the end of
the study period, the patients’ quality of life
was still significantly lower than the aver-
age utility score of the general population
(0.88) (Table 4).
Cost utility
Table 5 shows the incremental cost-
effectiveness ratios both for direct medical
costs per QALY gained and for total costs
per QALY gained. As we are comparing
three treatment options, we have reported
the results in the format suggested by Karls-
son & Johannesson (1996). The treatments
are ordered from least to most effective.
Comparison of the direct medical costs of
care as usual and CBT shows that CBT is
superior to usual care (with lower costs
and better outcomes), so an incremental
cost-effectiveness ratio is only calculated
for brief therapy v. CBT, yielding a value
of e262 857 per QALY gained. With regard
to total costs the same relationship applies
(CBT could achieve the same number of
QALYs at lower costs), so again only the
incremental cost-effectiveness ratio for brief
therapy v. CBT is calculated, yielding a
value of e222 956 per QALY gained.
To assess the uncertainty, we con-
structed acceptability curves for each treat-
ment by calculating the proportion of
bootstrap replicates for which that treat-
ment is optimal, for a number of threshold
incremental cost-effectiveness ratios (Fig. 1)
(Fenwick et al, 2001). Figure 1 relates to
the direct medical costs per QALY, and it
indicates that, taking uncertainty into ac-
count, CBT is optimal. However, the pre-
ference for CBT becomes less strong as
the threshold incremental cost-effectiveness
ratio increases. The same is true if all costs
are considered (data not shown).
Sensitivity analyses
In the sensitivity analyses of the missing
data, we recalculated the costs and QALYs
by performing linear extrapolation and
complete case analysis (Table 6). Again no
significant difference was found between
the groups in overall mean costs and
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Table 2 Mean directmedical costs and indirect costs1
Care as usual CBT Brief therapy
Number of patients 245 241 187
Number of sessions: mean (s.d.) 12 (14) 10 (7) 8 (11)
Costs (e): mean (s.e.)
MHC 1396 (107) 1180 (58) 941 (99)
Othermedical care 1964 (235) 1947 (239) 2738 (395)
Total directmedical costs 3360 (251) 3127 (255) 3679 (417)
Indirect costs 6151 (551) 6621 (683) 6537 (675)
Total costs (direct and indirect) 9511 (607) 9748 (747) 10216 (816)
CBT, cognitive^behavioural therapy; MHC, mental healthcare centre.
1. Using 2002 values.
Table 3 Percentage of respondents in paid employment with impediments, and short-term and long-term
absence fromwork by treatment group1
Care as usual CBT Brief therapy Total
Baseline
n 149 141 130 420
No impediments at work (%) 13 12 16 14
Impediments at work (%) 30 30 33 31
Absent fromwork for52 weeks (%) 15 11 12 13
Absent fromwork for52 weeks (%) 56 57 50 55
One-year follow-up
n 95 80 90 265
No impediments at work (%) 46 46 48 47
Impediments at work (%) 29 38 30 32
Absent fromwork for52 weeks (%) 8 15 11 11
Absent fromwork for52 weeks (%) 20 16 19 18
End of study (1.5 years)
n 86 80 77 243
No impediments at work (%) 52 63 43 53
Impediments at work (%) 33 30 40 35
Absent fromwork for52 weeks (%) 17 14 16 16
Absent fromwork for52 weeks (%) 12 8 17 12
CBT, cognitive^behavioural therapy.
1. The total percentagemay bemore than100% because respondentsmay have been absent fromwork (short term)
and had impediments or no impediments while working during the past 2 weeks.
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QALYs. When only 48% of the partici-
pants were used for the complete case ana-
lysis this resulted in comparable findings to
those of the linear extrapolation analysis,
but with much larger standard errors.
DISCUSSION
To our knowledge, this study is the first
long-term cost-utility analysis of brief
therapy in the Dutch mental healthcare
setting to be conducted from a societal
perspective. It demonstrated that brief
therapy was less costly to the MHCs than
CBT or care as usual. Taking into account
the direct medical healthcare costs in other
parts of the healthcare system, we found no
significant differences in costs between the
treatment groups, nor were there any signif-
icant differences in utility scores between
the groups. These findings suggest that the
cost savings resulting from brief therapy
were cancelled out by higher costs in other
areas of healthcare. Inclusion of the indirect
costs due to productivity losses did not
change our conclusion. In addition, our
study confirmed that the indirect costs due
to productivity losses were responsible for
the majority of the costs of depression and
anxiety to society. Over time, the indirect
costs declined significantly and there was
a significant improvement in health-related
quality of life for all three treatment
groups.
Sample selection
We conducted a large-scale multicentre ran-
domised trial in the setting of general mental
healthcare services in The Netherlands.
External validity may have been affected
by selection bias resulting from patients
either refusing to enter the study or being
lost to follow-up. Our data on refusal and
our missing data seem to be comparable
to those of other important trials (Lambert
& Ogles, 2004). Moreover, treatment
drop-out in this study was comparable to
that in the general population of MHC
patients (van der Sande et al, 1992). We re-
cruited patients with a wide range of mood
and anxiety disorders, comparable to a
normal population of out-patient mental
healthcare patients. Furthermore, the pa-
tients in our trial reported more (severe)
psychological symptoms at baseline (mean
score of 223 on the 90-item Symptom
Checklist (SCL–90) (Derogatis, 1977)) than
did a reference population of arbitrarily se-
lected Dutch psychiatric out-patients (mean
SCL–90 score¼204) (Arrindell & Ettema,
2003). There was no indication of any
selection bias leading to the enrolment of
only ‘mild’ cases in the study. Furthermore,
we found no significant differences in base-
line characteristics or mental health status
between patients who completed the study
and those who did not. Therefore there is
no compelling reason to believe that selec-
tion bias affected the external validity of
the study.
Study design
Unfortunately, this study did not provide an
opportunity to evaluate the cost-effectiveness
of psychological treatment compared with
natural recovery of the patient. The poten-
tial effect of antidepressant medication,
which was allowed in addition to the treat-
ment to which patients were randomised, is
also unclear. At baseline, 36% of the re-
spondents used antidepressant medication,
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Table 4 Utility scores by treatment arm at baseline, at1year and at the end of the study (1.5 years), and
QALYs per patient at the end of the study
Care as usual CBT Brief therapy
Number of patients 245 214 187
Baseline
Utility score (s.e.) 0.51 (0.02) 0.52 (0.02) 0.53 (0.02)
Number of patients 165 127 131
One-year follow-up
Utility score (s.e.) 0.64 (0.02) 0.68 (0.02) 0.64 (0.03)
Number of patients 147 111 126
End of study (1.5 years)
Utility score (s.e.) 0.69 (0.04) 0.65 (0.04) 0.71 (0.04)
QALYs (s.e.) 0.909 (0.03) 0.936 (0.03) 0.939 (0.03)
CBT, cognitive^behavioural therapy; QALYs, quality-adjusted life-years.










0.91 3360 CBT could achieve the
same number of QALYs at
lower cost than treatment
as usual
9511 CBT could achieve the
same number of QALYs at
lower cost than treatment
as usual
CBT 0.94 3127 9748
Brief
therapy
0.94 3679 262 857 10216 222956
QALYs, quality-adjusted life-years; ICER, incremental cost-effectiveness ratio; CBT, cognitive^behavioural therapy.
Fig. 1 Acceptability curves for the three treatment options, for directmedical costs per QALYgained.CBT,
cognitive^behavioural therapy; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
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and there were no significant differences
between the treatment groups.
Direct costs
It was not possible to distinguish between
healthcare utilisation for depression and/
or anxiety disorders and that for eventual
other general healthcare problems which
relied on other areas of the healthcare sys-
tem. However, this was equally true for
all three treatment groups. Furthermore,
data were collected on healthcare utilisa-
tion, which it was expected would be rele-
vant to the treatment of psychological
problems. Data on healthcare utilisation
other than sessions at the MHCs were col-
lected by self-report. A previous study has
indicated that such patients’ self-reports
are a valid source of data on days of hospi-
talisation and out-patient visits. However,
costs of medication may be underestimated
(van den Brink et al, 2004).
Indirect costs
Our study indicated that inclusion of the
indirect costs for patients with depression
and/or anxiety was highly relevant. We
did not assess productivity losses resulting
from reduced efficiency at work and from
unpaid work (e.g. household work), be-
cause of the practical and methodological
difficulties involved in measuring these
losses. Consequently, the actual productivity
losses to society were probably under-
estimated.
In a population that has social insur-
ance it is unlikely that respondents include
the societal impact of ill health in quality-
of-life measures, because they do not bear
the full consequences of their reduced pro-
ductivity (Brouwer et al, 1997; Meltzer &
Johannesson, 1999). Recently, an empirical
study by Sendi & Brouwer (2005) indicated
that respondents do not include the effect of
ill health on income if the instrument used
does not explicitly ask about this effect (as
is the case for the EQ–5D).
Cost-effectiveness
The results of our study are consistent with
the findings of a systematic review on the
effectiveness and cost-effectiveness of brief
psychological treatments for depression
(Churchill et al, 2001). The review sug-
gested that some forms of brief psychologi-
cal treatment, particularly those derived
from cognitive–behavioural models, are
beneficial in the treatment of people with
depression who are being managed outside
the hospital setting (Churchill et al, 2001).
A cost-effectiveness study by Pyne et al
(2003) estimated the cost per QALY of a
primary care intervention for women with
depression. Its findings suggested that en-
hanced care for women with depression
was more expensive and more effective
than usual primary care, the additional cost
being US$5244 per QALY.
Overall, we found no cost savings of
brief therapy over CBT or care as usual.
However, in terms of the MHCs, brief ther-
apy was a cost-effective treatment and may
help to reduce waiting lists. In routine prac-
tice, ‘stepped care’ is characterised not only
by fewer sessions, but also by an earlier
start after intake. Subsequently, the MHCs
may increase the quality of care that they
provide by a formalised approach, and be
more successful in meeting the preferences
of patients. This might allow redistribution
of some resources to the group of patients
who are not effectively treated. This treat-
ment policy should be supported by a mon-
itoring system for detecting inadequately
treated patients to ensure that there is a
timely switch to a more appropriate treat-
ment option.
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& Care as usual (‘matched care’) was notmore cost-effetive than brief psychological
therapy or cognitive^behavioural therapy (‘stepped care’).
& Brief psychological therapymay help to reduce thewaiting lists ofmental health
care centres.
& Brief psychological therapy reduces the costs of mental healthcare centres and
may allow redistribution of resources to the group of patients who are ineffectively
treated.
LIMITATIONS
& Data on the use of other healthcare services and on short-term absence from
work were collected frompatients with a limited recall period.
& Complete service use data for other healthcare services and data on absence from
work for the total follow-up period (1.5 years) were available for less than half of the
respondents.
& The study provided no opportunity to evaluate the cost-effectiveness of
psychological treatment comparedwith natural recovery of the patient.
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